Kymera Therapeutics

Kymera Therapeutics Presents New Data Demonstrating Proof-of-Degradation Using Novel Tissue-Restricted E3 Ligase

Novel E3 ligase identified by Kymera’s Whole-Body Atlas is expressed in selected tissues while broadly expressed in cancer cells Novel STAT3 degrader enabled by Pegasus TM platform, and based on identified novel ligase, demonstrates proof-of-concept degradation across multiple in vitro cancer cell